TAK-701, a humanized monoclonal antibody to hepatocyte growth factor, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with an EGFR mutation.
about
c-Met as a Target for Personalized TherapyLigand-triggered resistance to molecular targeted drugs in lung cancer: roles of hepatocyte growth factor and epidermal growth factor receptor ligandsResearch Progress of HGF/c-MET Inhibitor in the Treatment of Non-small Cell Lung CancerEGFR-TKI resistance in NSCLC patients: mechanisms and strategiesHepatocyte Growth Factor/c-Met Signaling in Head and Neck Cancer and Implications for TreatmentAnthraquinone Derivatives as Potent Inhibitors of c-Met Kinase and the Extracellular Signaling Pathway.The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment.Non-agonistic bivalent antibodies that promote c-MET degradation and inhibit tumor growth and others specific for tumor related c-MET.EGFR Mutant Structural Database: computationally predicted 3D structures and the corresponding binding free energies with gefitinib and erlotinib.Resistance to targeted cancer drugs through hepatocyte growth factor signalingMolecular mechanisms contributing to resistance to tyrosine kinase-targeted therapy for non-small cell lung cancerTargeting the HGF/Met signaling pathway in cancer therapyInitial testing (Stage 1) of TAK-701, a humanized hepatocyte growth factor binding antibody, by the Pediatric Preclinical Testing Program.Progress of antibody-based inhibitors of the HGF-cMET axis in cancer therapy.Emerging antibody combinations in oncology.MET: a promising anticancer therapeutic target.Echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-targeted therapy for advanced non-small cell lung cancer: molecular and clinical aspects.Focus on the potential role of ficlatuzumab in the treatment of non-small cell lung cancer.Developing biomarkers to predict benefit from HGF/MET pathway inhibitors.Targeting the oncogenic Met receptor by antibodies and gene therapy.MET inhibition in lung cancer.Prognostic and predictive value of MET deregulation in non-small cell lung cancerPromise and challenges on the horizon of MET-targeted cancer therapeuticsC-Met as a potential target for the treatment of gastrointestinal cancer: Current status and future perspectives.Development of antibody-based c-Met inhibitors for targeted cancer therapy.MET overexpression and gene amplification in NSCLC: a clinical perspective.The c-Met receptor: Implication for targeted therapies in colorectal cancer.Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer.A Review of Anti-Angiogenic Targets for Monoclonal Antibody Cancer TherapyPhase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC.Reduction in Hepatocyte Growth Factor Serum Levels is Associated with Improved Prognosis in Advanced Lung Adenocarcinoma Patients Treated with Afatinib: a Phase II Trial.Status of Agents Targeting the HGF/c-Met Axis in Lung Cancer
P2860
Q26775483-DC1519C3-99E5-4D9F-8CD4-1898E9AC06A6Q26829104-59025A14-1359-4145-8557-AE0E4C1D2E5AQ27006349-F1775DE9-DE74-492A-9DD6-7590137268C3Q28394310-DBCF6B45-48AC-46BA-96F0-B9B8CE008108Q33607965-40560B60-22FD-4F21-92CB-CE426F11BBD3Q33635671-AE7AD6F2-E4EF-4CF5-B518-BF4C453335B2Q33769429-7295672F-1CF0-4CF2-8126-696DE383C34CQ34236834-18C40F7A-4FCC-4D84-BBD2-B7C7B65EEA94Q35606916-997AB3BB-29AA-4032-8AAE-A6A11B2AD61EQ36189390-DBD56CE9-DCD2-4D4A-BF8C-6C5D7F23179DQ36814305-75575E23-2BBC-45EA-839C-D2C0BC4D8292Q37013777-B51926FC-BB99-4053-9BBA-B76B5079FB7BQ37653512-D71FD51F-CF48-4262-AFCF-E30007A2C8D2Q37739477-0036A8E0-93D8-4381-A8AD-D5EAB083FB42Q37893414-11460654-A324-47CF-88DA-005C3205382CQ38008247-8CFD6B3E-6EEE-44A7-8B82-9D499220D15BQ38008456-4876E8DB-B0B4-4456-914E-75F0FF187E3CQ38089600-832C6366-6628-40F5-A89E-81EA9A5A468AQ38150768-BC2D415D-E862-433D-A745-C6388028A704Q38216590-B1ADEEF8-D01F-41F2-BA43-0C2DD8400E23Q38390016-082B9E9F-2FCC-4B7D-AB3E-15D4F7DE96B4Q38493294-144530BA-4F9C-4AEC-9565-819AD1801782Q38502350-8B890254-526C-4FEC-8128-A5011E68F5DDQ38771978-69BA277B-193C-450D-9CB4-29D999A13060Q38912279-4C4A5BCC-361B-4A77-BEA9-2E2FDD6356A6Q38956316-C572B2EB-00D2-41E7-B095-2610CEB55288Q39274990-C8EF5130-D6CF-43D0-82AE-60FFD0A11F4CQ39559573-57E63483-245E-47A0-9E91-F5B6E4BB6682Q41574359-AC084F7C-F821-41D6-A015-8E70F95D6598Q49962860-BFF05577-CD6B-425E-A72F-A79FA6BBC24FQ50221702-2FA03284-C972-4EB2-AE97-0FFC15DC46DAQ58726253-BBD6B754-A0DE-4340-8119-97E45FB1F022
P2860
TAK-701, a humanized monoclonal antibody to hepatocyte growth factor, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with an EGFR mutation.
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
TAK-701, a humanized monoclona ...... cancer with an EGFR mutation.
@ast
TAK-701, a humanized monoclona ...... cancer with an EGFR mutation.
@en
type
label
TAK-701, a humanized monoclona ...... cancer with an EGFR mutation.
@ast
TAK-701, a humanized monoclona ...... cancer with an EGFR mutation.
@en
prefLabel
TAK-701, a humanized monoclona ...... cancer with an EGFR mutation.
@ast
TAK-701, a humanized monoclona ...... cancer with an EGFR mutation.
@en
P2093
P2860
P1476
TAK-701, a humanized monoclona ...... cancer with an EGFR mutation.
@en
P2093
Erina Hatashita
Haruka Yamaguchi
Isamu Okamoto
Kaoru Tanaka
Kazuhiko Nakagawa
Kazuto Nishio
Kiyoko Kuwata
Masahiro Fukuoka
Tokuzo Arao
Wataru Okamoto
P2860
P304
P356
10.1158/1535-7163.MCT-10-0481
P50
P577
2010-08-17T00:00:00Z